Moustafa Moustafa, MD
Nephrology · Orangeburg, SCNPI 1356431449
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $417,735 of the $615,928 with a category attached, or 67.8%. Fresenius USA Marketing, Inc. accounts for 87.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $232,449 and has fallen 99.5% since, to $1,074 in 2025. Among nephrology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,201 payments — averaging $512.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$540K
- AstraZeneca$23K
- Amgen$23K
- GSK$8K
- Akebia Therapeutics Inc$7K
- Vifor Pharma, Inc.$5K
- plus $9K from 23 others
Across 993 payments — averaging $2410.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$522K
- OPKO Pharmaceuticals, LLC$362K
- Genentech, Inc.$273K
- AstraZeneca$239K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$183K
- Bayer$175K
- plus $640K from 10 others
What the payments were for
- Consulting fees$8,0851%
- Speaking & faculty fees$417,73568%
- Travel & lodging$167,71227%
- Food & beverage$22,1834%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 883 | $540,110 |
| AstraZeneca(2 entities) | 63 | $23,466 |
| Amgen(2 entities) | 55 | $23,058 |
| GSK | 11 | $8,225 |
| Akebia Therapeutics Inc | 11 | $6,893 |
| Vifor Pharma, Inc. | 33 | $5,434 |
| Calliditas Therapeutics US Inc. | 18 | $2,044 |
| Novartis | 3 | $1,469 |
| Novo Nordisk AS | 4 | $1,281 |
| Astrazeneca UK Limited | 6 | $1,064 |
| Aurinia Pharma U.S., Inc. | 18 | $565 |
| Otsuka America Pharmaceutical, Inc. | 17 | $451 |
| Bayer | 17 | $298 |
| Mallinckrodt Enterprises LLC | 3 | $262 |
| OPKO Pharmaceuticals, LLC | 11 | $204 |
| Ardelyx, Inc. | 7 | $168 |
| Mallinckrodt Hospital Products Inc. | 3 | $162 |
| Renalytix AI, Inc. | 6 | $116 |
| Boehringer Ingelheim | 5 | $113 |
| Travere Therapeutics, Inc. | 7 | $103 |
| Corcept Therapeutics | 5 | $96 |
| Nxstage Medical, Inc. | 2 | $80 |
| Scpharmaceuticals Inc. | 3 | $61 |
| Ultragenyx Pharmaceutical Inc. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 3 | $40 |
| Sanofi | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$615,928 in reported general payments places this provider in the 95th percentile of 180 nephrology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 182 | $440,828 |
| FarxigaDapagliflozin Propanediol | 212 | $161,778 |
| XphozahTenapanor Hcl | 21 | $123,551 |
| RayaldeeCalcifediol | 34 | $43,011 |
| LokelmaSodium Zirconium Cyclosilicate | 43 | $36,601 |
| KerendiaFinerenone | 41 | $31,586 |
| Sevelamer Carbonate | 175 | $25,470 |
| AuryxiaFerric Citrate | 25 | $24,873 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $23,812 |
| Lanthanum Carbonate | 16 | $19,307 |
| FosrenolLanthanum Carbonate | 12 | $16,148 |
| Cinacalcet Hcl | 16 | $5,502 |
| DapagliflozinDapagliflozin Propanediol | 11 | $5,364 |
| Calcitriol | 143 | $3,313 |
| Nifedipine ErNifedipine | 171 | $3,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $540,110 | $440,828182 claims |
| AstraZenecaFarxiga, Lokelma | $23,466 | $198,379255 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $204 | $43,01134 claims |
| BayerKerendia | $298 | $31,58641 claims |
| Akebia Therapeutics IncAuryxia | $6,893 | $24,87325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 nephrology providers in South Carolina.
Other nephrology in Orangeburg
- Jalal Eddin HakmeiOrangeburg$7K
- Jessica ColemanBeaufort$930K
- Harold SzerlipCharleston$229K
- Barry GorlitskyGreenville$195K
- Blake ShustermanGreenville$66K
- Martin WebbBeaufort$66K
- Mohammed AlzubaidiSumter$54K
- Joshua LipschutzCharleston$44K
- Renee EllisColumbia$40K
- Charles BunkeCharleston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.